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ABSTRACT 
The liver is the main place for phase II metabolism and transport of xenobiotics mediated 
by Mrp2, leading to elimination of conjugated metabolites into bile. In the gastrointestinal 
tract, phase II enzymes and Mrp2 are preferentially localized in the proximal region of the 
small intestine, particularly at the tip of the villus. In pregnant rats, conjugating enzymes 
(e.g. UGT and GST) and Mrp2-mediated transport of xenobiotics are decreased when 
compared to normal females, whereas these systems are preserved in small intestine, 
suggesting a complementary role for this tissue. After delivery, these same enzymes 
increase their expression and activity, being maximal during the last week of lactation. 
Mrp2 protein in liver also recovers and reaches the control level by the end of the lactation 
period. Post-partum rats exhibit a significant increase in development of the digestive tract 
in association with induction of phase II enzymes and Mrp2 expression and activity. 
Although the factors involved in regulation of protein expression may not be the same for 
conjugating enzymes and Mrp2 in the different experimental situations or tissues studied, 
their common localization and co-regulation provide evidence that they may work in 
cooperation. This is not surprising if we consider that most of the substrates for MRPs are 
the products that result from phase II reactions. Here, we provide a brief description of 
regulation of major phase II enzymes and Mrp2 during pregnancy and lactation, as 
particularly seen in the rat. 
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During pregnancy and lactation important hormonal changes occur which mainly involve 
increased levels of estrogens, progestogens and lactogenic factors. These hormones act on 
metabolizing systems in maternal liver producing a variety of effects which may have 
physiological, pharmacological and toxicological consequences. This results in changes in 
the capability for drug biotransformation and elimination. For lipid-soluble drugs, in 
particular, these consequences are extended to fetuses and also to newborns since nearly all 
drugs administered to mothers are detectable in maternal milk [1]. Most of the studies of 
xenobiotic metabolism during pregnancy and lactation performed in experimental animal 
models were concentrated on oxidative and reductive biotransformations, rather than in 
conjugation reactions. It is generally accepted that gestation depresses rat hepatic 
metabolism associated to the endoplasmic reticulum and decreases the content of 
cytochrome P450 in rats [2]. Because of the increase in liver weight, it is not clear whether 
the absolute capability of these animals for drug metabolism is really decreased. 
The phase II or post-oxidative biotransformation system comprises a wide spectrum of 
enzymes that catalyze the incorporation of polar groups into hydrophobic molecules, thus 
decreasing hydrophobicity and eventually toxicity of the parent compounds (Figure 1). 
The multidrug resistant proteins (MRPs) represent a family of transporters that exhibit high 
expression in tumoral cells but are also expressed normally in epithelial cells. Mrp2, one of 
the members of the family, is preferentially localized in the apical membrane of 
hepatocytes, renal tubular cells and enterocytes and is involved in secretion of a wide 
spectrum of conjugated compounds [3, 4, 5,]. Here we report studies conducted to 
determine the influence of pregnancy and lactation on expression of hepatic and intestinal 
phase II reactions mainly involving UDP-glucuronosyltransferase (UGT) and Glutathione-
S-transferase (GST). Because most Mrp2 substrates are conjugated derivatives of 
endogenous and exogenous compounds (drugs, carcinogens, etc), we compiled also studies 




















Figure 1. Biotransformation and transport systems. 
Phase I reactions consist of oxidation, reduction and methylation that convert original compounds into more 
polar derivatives. Phase II involve conjugation reactions; substances (eventually Phase I reaction products) 
are coupled with a conjugating agent (e.g. glucuronic acid, glutathione, sulfate, acetate) and further converted 
to more hydrophilic, non toxic, derivates. Water soluble products are finally pumped out of the cells through 
the cell membranes with participation of specific transporters like the ABC members multidrug resistance-




Hepatic and intestinal metabolism and transport of xenobiotics. 
 
We are daily exposed to many xenobiotics that are naturally present in the environment in 
addition to a wide variety of pollutants, drugs and food additives. They may enter the body 
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through inhalation, dermal absorption and incorporation into the gastrointestinal tract [6]. 
In addition to naturally occurring xenobiotics, there are hundreds of dietary contaminants 
that are intentionally added to food, which are daily incorporated into the gastrointestinal 
tract. Lipid-soluble chemicals readily cross biological membranes and distribute into fluid 
compartments and particularly in highly perfused tissues. After that, the chemicals may 
undergo redistribution into tissues that may act as storage reservoirs. In order to facilitate 
their elimination, the enzyme systems produce metabolites that are generally more water-
soluble. Most drugs undergo first-pass metabolism in which biotransformation in 
hepatocytes and/or enterocytes prevents the distribution of intact chemicals throughout the 
body and facilitates their elimination from the body [7]. The liver represents the main place 
for drug biotransformation reactions, including phase I and II reactions, whereas the small 






Figure 2. Fate of orally incorporated xenobiotics. Phase II biotransformation reactions and MRPs may act 
coordinately to metabolize hydrophobic xenobiotics entering the body via the gastrointestinal tract. Once into 
the intestinal cell, a hydrophobic xenobiotic can be transported without change to the portal vein, probably by 
simple diffusion. The xenobiotic then reaches the hepatocyte, the main place for phase II reactions and Mrp2-
mediated transport, where it is biotransformed and secreted into bile. Once in the intestinal lumen, the 
conjugated xenobiotic may be eliminated together with the feces, hydrolyzed (e.g. by β–glucuronidase) and 
reabsorbed, or directly reabsorbed in the intact form. The presence of Mrp2 on the apical membrane of the 
enterocyte may contribute to prevent reabsorption (see Fig 3 for details). The kidney may be an alternative place 
for elimination of xenobiotics suffering phase II metabolism since it expresses conjugating enzymes and Mrp2. 
Glomerular filtration of conjugated derivatives may also account for renal elimination of xenobiotics. 
Basolateral MRPs (e.g. Mrp3) in hepatocytes can pump conjugated xenobiotics to blood thus initiating this 
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alternative route of elimination. The balance between transport through the apical (canalicular) or basolateral 
(sinusoidal) membrane in liver would determine the definitive fate of the ingested xenobiotic (feces vs urine). 
 
 
In recent years, molecular biologists have introduced the possibility of studying the 
contribution of the different enzyme isoforms involved in biotransformation of xenobiotics 
as well as the molecular basis of regulation of their expression. It is now known that the 
small intestine may express phase I and II isoenzymes different than those present in liver, 
which could result from a different regulation of the genetic machinery. Several phase II or 
conjugating enzymes are good examples of such differences. The UGT isoenzymes 
UGT1A7, 1A8 and 1A10, belonging to UGT family 1, are predominantly expressed in the 
gastrointestinal tract, in contrast to most other UGT forms which are expressed in the liver 
[8]. In some cases different isoenzymes may share substrate specificity. For example, 
UGT1A6 that is mainly expressed in the liver, similarly to UGT1A7 is involved in 
conjugation of planar phenols. Thus, they may act independently as a double barrier to 
prevent absorption of natural occurring phenols of plant materials. Expression of different 
isoforms of phase II biotransformation enzymes between liver and intestine was also 
described for GST. While subunits belonging to GST family alpha and mu are 
predominantly expressed in the liver, pi subunits are poorly expressed in this tissue except 
when a malignant tumor is present [9]. In contrast, pi subunits present a significant 
constitutive expression in small intestinal tissue, in addition to alpha and mu classes [9]. Pi 
subunits are almost the unique classes of GST expressed in colon. Functional differences in 
terms of substrate specificity and response to inducers were associated to the different 
pattern of subunits between tissues. 
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Figure 3. Phase II biotransformation and MRP2-mediated transport of xenobiotics in the enterocyte.  
Hydrophobic xenobiotics freely enter the cell by diffusion through the basolateral or apical membrane in the 
enterocyte. They then suffer phase I and/or phase II biotransformation reactions resulting in more hydrophilic 
derivatives. Drug transporters mediate elimination of such derivatives from the cell. In the case of conjugation 
reactions (e.g. with glutathione), the product is further secreted into the intestinal lumen in a process mediated 
by Mrp2 (A). Alternatively, MRP substrates may be secreted through the basolateral membrane (B), and 
incorporated into blood circulation. Mrp3, one of the candidates to mediate this latter process, was demonstrated 
to be present in both hepatocytes and enterocytes. Panel B shows how these processes particularly affect the 
xenobiotic 1-chloro-2,4-dinitrobenzene (CDNB). 
 
Contribution of the liver and intestine to first-pass metabolism depends not only on their 
respective enzyme activities but also on the capacity of transporters expressed at the 
plasma membrane level to secrete metabolized xenobiotics [10, 11]. While the coordinate 
action of phase I metabolizing enzymes and the transporter Multidrug Resistant Protein 
(MDR1) p-glycoprotein was extensively analyzed in previous reports [12, 13], little is 
known about the coordinate action of phase II systems and transporters specialized in 
conjugated xenobiotics, such as MRPs. Although the route of entry of phase II substrates in 
hepatocytes and enterocytes may be the basolateral membrane, the enterocyte presents an 
alternative way for substrates entering the cell from the lumen (dietary xenobiotics and 
drugs) (Figs 2 and 3). After conjugation mediated by microsomal UGT or cytosolic GST 
or sulfotransferase, the conjugated derivatives could be secreted through the apical or 
basolateral membrane in a process mediated by MRPs. 
 
   
 
Expression and activity of phase II enzymes and Mrp2 in pregnancy. 
 
 
UDP-glucuronosyltransferase (UGT) specific activity is decreased in liver from pregnant 
rats when compared to non-pregnant controls, affecting substrates such as bilirubin, phenol 
derivatives, estradiol and estrone [2]. Although the expression of the different GST 
subunits was not evaluated in pregnancy, it was reported that GST activity towards 1-
chloro-2,4-dinitrobenzene (CDNB) is increased at late lactation [2] Thus, differences 
between regulation of UGT and GST activities are apparent in pregnancy. We evaluated 
the expression (protein and mRNA) of the UGT isoforms involved in conjugation of 
phenols (UGT1A6), bilirubin (UGT1A1 and 5) and estradiol in the 17β-OH group 
(UGT2B1) at late pregnancy in the rat [14]. The western blot studies revealed a decrease 
(about 50%) in the level of all the isoforms tested. Interestingly, the levels of the respective 
mRNAs were not affected by pregnancy, suggesting post-transcriptional downregulation of 
UGT protein. The mechanism by which UGTs are downregulated in pregnant rats is still 
not clarified. Treatment of female rats with ethynylestradiol (EE) decreased UGT activity 
towards estradiol (3-OH and 17β-OH groups) in a similar magnitude as it was observed in 
pregnancy [15]. In an attempt to reproduce the decrease in bilirubin UGT activity and in 
maximal biliary excretion of the pigment observed in pregnant rats, Muraca et al [16] 
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administered a combination of estradiol and progesterone to ovariectomized rats leading to 
plasma levels of the hormones similar to those observed in pregnancy. Treatment with this 
appropriate combination of the steroids failed to reproduce the effects observed in pregnant 
rats. The authors suggested that other steroids might be involved or that other hormones 
might be required to allow the effect of estrogens and progestogens to became manifest, 
thus exerting a permissive effect. The reason by which the synthetic estrogen EE but not 
the natural estrogens in combination with progestogens, was able to mimic downregulation 
of UGTs in maternal rat liver is not clear, but it is interesting to note that EE administration 
is able to decrease expression of UGT proteins. Treatment of female rats with 5 mg of EE 
per Kg of body weight (twice daily) for 5 days, was able to decrease the level of the 
hepatic UGT isoforms 1A1, 1A5 and 2B1, in a similar magnitude observed for pregnancy 
[14]. However, it is not possible to generalize because of the occurrence of inter-species 
differences in the regulation of the expression and activity of metabolizing enzymes. For 
example, it was observed that elimination rates of drugs metabolized by certain isoforms of 
UGT, such as UGT1A4 and UGT2B7, are increased in pregnant women when compared to 
non-pregnant women [17, 18]. 
Biliary excretion of several Mrp2 substrates is also decreased in rats in the latter stages of 
pregnancy in accordance with a clear decrease in the level of Mrp2 in liver plasma 
membrane detected by western blotting but preserved level of Mrp2 mRNA detected by 
northern blotting [19]. The mechanism by which Mrp2 are downregulated in pregnant rats 
was not clarified, but it was observed that treatment of male rats with EE decreased Mrp2 
protein level in liver and was able to mimic the dissociation between protein and mRNA 
[20]. These data would suggest that hormonal factors (e.g. sex steroids) affect Mrp2 
expression post-transcriptionally, thus leading for example, to an impairment of protein 
synthesis, or to an increase in protein degradation. Alternatively, a redistribution of protein 
molecules to a compartment distinct from the canalicular membrane (e.g. intracellular 
vesicles) may explain the decreased levels observed in pregnant or EE treated rats. The 
question about whether decreased capacity to metabolize and secrete Mrp2 substrates into 
bile in pregnant animals could increase toxicity of several endogenous and exogenous 
compounds to the maternal liver, and in addition, increase the risk of exposure to the 
fetuses, is controversial. Taken glucuronidation and subsequent transport of bilirubin as a 
model substrate, one can speculate that depending on the way to express the data, different 
conclusions arise. For example, bilirubin UGT activity was decreased in pregnant rats 
when expressed per mg of protein or per g of liver. However, because the liver weight is 
increased in these animals, UGT activity did not change when expressed per whole liver 
[16]. Because body weight is also higher in pregnant rats, bilirubin conjugation is again 
decreased when the activity is normalized per body weight. Altered metabolism of 
bilirubin in pregnant animals may result from altered UGT activity or from a reduced 
availability of the cosubstrate of the reaction, i.e. UDP-glucuronic acid. Unfortunately, 
there is no information available on UDP-glucuronic acid levels in pregnancy. Dean et al 
[21] analyzed the pharmacokinetic of salicylate, which is mainly metabolized in liver by 
conjugation with glucuronic acid, in pregnant rats. They found that these animals showed a 
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significant decrease in body weight-normalized total clearance but no change in the 
absolute glucuronide or total clearance. However, because the biological half-life of 
salicylate was significantly increased in pregnant rats, the authors speculated that 
pregnancy is associated with a reduction in the capability of metabolizing salicylate in 
these rats. 
In a recent study, we demonstrated that expression of Mrp2 protein as well as mRNA is 
preserved in small intestine during pregnancy [22]. The data clearly indicate a differential 
regulation of Mrp2 expression between liver and intestine during pregnancy. In the same 
study we analyzed the capacity of enterocytes to secrete GS-DNP, the conjugated 
derivative of CDNB, through the apical membrane, a process that was postulated to be 
mainly mediated by Mrp2. Because it is not possible to obtain inside-out vesicles from the 
apical membrane of the enterocyte, different strategies, such as Caco-2 cells, isolated 
intestinal sacs, Ussing chambers and preloading of BBMVs have been used to study 
intestinal secretion mediated by ABC transporters. We analyzed transport of GS-DNP in 
the proximal small intestine using the everted intestinal sac model. The parent compound 
of GS-DNP, CDNB, was added to the mucosal compartment of the intestinal sac, and the 
conjugated derivative generated endogenously was detected in the same compartment (Fig 
3). We observed that secretion of GS-DNP from the cell to the mucosal compartment, most 
probably mediated by Mrp2, was the rate-limiting step of the overall process and that it 
was preserved in pregnant rats. This was consistent with preserved expression of Mrp2, 
reinforcing the postulate that Mrp2 is at least partially responsible for GS-DNP transport. 
Because UGTs and Mrp2 are down regulated in liver during pregnancy, secretion of 
conjugated derivatives across the apical membrane of the proximal intestinal cells may 
represent an alternative pathway to prevent toxicity of xenobiotics, particularly those 
entering the body via the intestinal tract.  
 
 
Expression and activity of phase II enzymes and Mrp2 in lactating mothers. 
 
 
The activity of the conjugating enzymes, UGT and GST, are significantly increased in liver 
[23, 24] and small intestine [25] of female post-partum rats. Fourteen and 21 days after 
delivery, lactating rats exhibit an increase in the activity of UGT towards p-nitrophenol and 
in GST activity towards CDNB, primarily due to an increase in expression of specific 
isoforms. By western blotting we demonstrated that hepatic GST activity was increased 
mainly at expenses of the Mu subunits GSTM1 and GSTM2 while in intestine GST 
activity was increased mainly at expenses of the Pi subunit GSTP1. The increase in the 
activity of UGT towards p-nitrophenol observed in liver correlated well with an increased 
expression of the UGT1A6 also detected by western blotting. A northern blot study 
demonstrated that the upregulation was at transcriptional level. Because the liver weight is 
significantly increased in post-partum animals one can speculate that the absolute activity 
is also increased in these rats. In addition, we observed that hepatic content of UDP-
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glucuronic acid is also increased in post-partum rats [23], suggesting an increased 
capability for UGT-mediated reactions in vivo. Administration of ovine prolactin to 
ovariectomized rats was able to reproduce GST and UGT changes, strongly suggesting that 
this hormone was the main factor involved in their regulation post-partum [24, 25]. To 
check whether Mrp2 follows a parallelism with phase II enzymes in lactating rats we 
studied expression of the pump in the post-partum liver [19] and intestine [22]. We found 
that hepatic Mrp2 protein, which was downregulated during pregnancy, slowly recovered 
along the lactation period reaching the same values observed in normal rats. Intestinal 
levels of Mrp2 protein and mRNA, which were preserved in pregnant rats, increased 
significantly with respect to controls, reaching a maximum at the latter stage of lactation 
(about 100% increase). The in situ analysis of Mrp2 levels by immunohistochemistry 
brought additional information. We observed that in agreement with the increase in the size 
and weight of the intestine in post-partum rats (about 130% with respect to control 
females), the villus exhibited a substantial increase (about 100%) in height. We did not 
analyze quantitatively the in situ expression of Mrp2, however, no substantial differences 
were observed in the intensity of the immunostaining between groups. We speculated that 
because the size of the villus, and thereby the villus surface, changed substantially between 
control and post-partum rats, the increased expression of Mrp2 protein observed 
postpartum in western studies results from preferential development of the regions where 
Mrp2 is better expressed (i.e., the upper villus), rather than derive from a specific increase 
in Mrp2 expression. Analysis of CDNB metabolism and transport in the everted sac model 
revealed that Mrp2-mediated secretion of GS-DNP into the mucosal compartment was also 
increased in jejunum from lactating rats in agreement with the increased expression of 
Mrp2. In additional experiments using the same model, we analyzed whether GS-DNP 
added to the mucosal compartment is transported to the serosal compartment in intestinal 
sacs from jejunum, ileum and colon of control, pregnant and post-partum rats. This study 
brought information about whether GS-DNP, once secreted into the lumen, may be 
reabsorbed, thus decreasing the efficiency of the secretory process. The data indicated that 
transport of GS-DNP was similar among the different regions of the intestine in control 
and pregnant rats but was significantly decreased in jejunum from post-partum animals. It 
is possible that the increased expression of Mrp2 in the proximal region of the intestine in 
lactating rats contributes not only to facilitate secretion but also to prevent reabsorption of 
the conjugated derivative of CDNB from the lumen. 
Food intake is greatly increased in post-partum rats (2-4 fold) with respect to normal 
females, particularly at the latter stage of lactation (14 to 21 days after delivery). This 
implies adaptation of the intestinal tract to satisfy the increased need for absorption of 
nutrients, e.g. by increasing the mucosal surface. The absorption and interaction of 
potentially toxic compounds with intestinal cells, particularly dietary xenobiotics, is also 
expected to increase. In consequence, increased expression of phase II enzymes and Mrp2 
may act coordinately to prevent the absorption of dietary xenobiotics. Interestingly, the 
increase in expression of phase II enzymes and Mrp2 was maximal during the last week of 
the lactation period [22] in agreement with the maximal increase in food intake and 
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intestinal hypertrophy. Because prolactin was not involved in these changes, we speculated 
that the factors involved in UGT, GST and Mrp2 regulation during lactation are different, 






Figure 4. Main variations in Phase II reactions and Mrp2 in liver and intestine from pregnant and postpartum 
rats. Phase II enzymes UGT and GST variations are representative of overall changes in conjugation 
reactions. For details on specific changes in the different isoforms of UGT or GST as well as in regulation of 







Literature on regulation of biotransformation and transport of xenobiotics during 
pregnancy and lactation is scarce, and unfortunately, no significant updates were provided 
in the last years on this particular. Most of the evidence, supporting significant regulation 
of these systems in liver and intestine, comes from experiments performed in rats. Fig 4 
summarizes major changes specifically observed in phase II reactions and Mrp2 during 
pregnancy or lactation in the rat. Due to potential differences in regulation of human vs 
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